Use of High-Intensity Statin Strategy. Are the Guidelines Followed?

Costa, Yanina B. Castillo; Mauro, Víctor M.; Charask, Adrián; Fairman, Enrique; Buhezo, Hugo; Barrero, Carlos

doi:10.7775/rac.v86.i1.11430

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless of atherothrombotic risk classification, high-intensity statin medication at discharge after an acute myocardial infarction was linked with fewer major adverse cardiovascular events at five years, with the biggest absolute reduction reported in the high-risk TRS-2P class (Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention) [ 33 ]. This study result aligns with a few recent studies with retrospective database analyses, which showed the benefit of high-intensity statin use for secondary prevention of cardiac arrest, recurrent MI, and the need for revascularization [ 27 , 34 ]. Thus, HIS is highly recommended for secondary prevention to be applied among post-hospitalized ACS patients in Indonesia.…”

Section: Discussionsupporting

confidence: 90%

Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Dewi,

Thavorncharoensap,

Rahajeng

2024

Egypt Heart J

View full text Add to dashboard Cite

Background Post-hospitalized acute coronary syndrome (ACS) patients in Indonesia National Insurance does not pay for the use of high-intensity statin (HIS) for secondary prevention after ACS hospitalization. Moreover, a cost–utility analysis needs to be conducted to evaluate the cost-effectiveness of prescribing HIS and low-to-moderate-intensity statin (LMIS) per quality-adjusted life year (QALY). This study aimed to estimate the cost–utility of long-term HIS treatment in post-hospitalized ACS patients in Indonesia compared to current practice. Results This study compared the economic outcomes of long-term HIS and LMIS in Indonesian post-hospitalized ACS patients. A lifetime Markov model predicted ACS-related events, costs, and QALY from a payer perspective. A systematic review estimated treatment-specific event probabilities, post-event survival, health-related quality of life, and Indonesia medical-care expenses from published sources. This study conducted probabilistic sensitivity analysis (PSA) using 1000 independent Monte Carlo simulations and a series of one-way deterministic sensitivity analyses utilizing a tornado diagram. The economic evaluation model proved that intensive HIS treatment can increase per-patient QALYs and care expenditures compared to LMIS. The use of HIS among post-hospitalized ACS patients had ICER 31.843.492 IDR per QALY gained, below the Indonesia willingness-to-pay (WTP) for terminal disease and life-saving treatment. Conclusion From the Indonesia payer perspective, using HIS for post-hospitalized ACS patients in Indonesia is cost-effective at 31.843.492 IDR per QALY gained.

show abstract

Section: Discussionsupporting

confidence: 90%

Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Dewi,

Thavorncharoensap,

Rahajeng

2024

Egypt Heart J

View full text Add to dashboard Cite

show abstract

“…Most studies were conducted in Brazil [ 3 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 ]. Six studies were conducted in Argentina [ 59 60 61 62 63 64 ], four in Chile [ 65 66 67 68 ], four in Colombia [ 69 70 71 72 ], three in Uruguay [ 73 74 75 ] and two were multi-country studies conducted in Argentina, Brazil, Chile and Colombia [ 12 ] and Brazil and Suriname [ 76 ]. The most common language of the articles was English (58 articles), followed by Spanish (11 articles) and Portuguese (4 articles).…”

Section: Resultsmentioning

confidence: 99%

Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis

Marzà-Florensa

Drotos

Gulayin

et al. 2022

View full text Add to dashboard Cite

Background: Coronary heart disease (CHD) is the most common cause of death globally, and clinical guidelines recommend cardioprotective medications for patients with established CHD. Suboptimal use of these medications has been reported, but information from South America is scarce. Methods: We conducted a systematic review on prevalence of secondary prevention medication in South America. We pooled prevalence estimates, analysed time-trends and guideline compliance, and identified factors associated with medication use with meta-regression models. Results: 73 publications were included. Medication prevalence varied by class: beta-blockers 73.4%(95%CI 66.8%–79.1%), ACEI/ARBs 55.8%(95%CI 49.7%–61.8), antiplatelets 84.6%(95%CI 79.6%–88.5%), aspirin 85.1%(95%CI 79.7%–89.3%) and statins 78.9%(95%CI 71.2%–84.9%). The use of beta-blockers, ACEI/ARBs and statins increased since 1993. Ten publications reported low medication use and nine reported adequate use. Medication use was lower in community, public and rehabilitation settings compared to tertiary centres. Conclusion: Cardioprotective medication use has increased, but could be further improved particularly in community settings.

show abstract

Use of High-Intensity Statin Strategy. Are the Guidelines Followed?

Cited by 2 publications

References 0 publications

Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis

Contact Info

Product

Resources

About